GeoVax Labs, Inc.

GeoVax Labs maintains a fragile capital structure characterized by high liquidity risk and substantial dilution pressure. The company holds $1.27 million in cash and equivalents against total liabilities of $2.49 million, resulting in a current ratio of 1.06, which sits at the lower bound of comfort ranges for operating continuity. Total equity stands at a nominal $493,770, reflecting accumulated losses that have eroded the balance sheet. The debt-to-equity ratio is reported as 0.0, indicating an absence of traditional interest-bearing debt, but the reliance on equity financing is evident in the significant warrant overhang and recent capital raises. The market capitalization of $2.54 million trades at a price-to-book ratio of 5.14, suggesting the market assigns value to future optionality rather than current book assets.

Profitability metrics are deeply negative, consistent with a pre-revenue clinical-stage entity. Net income for Q1 2026 was -$5.26 million, driven by operating losses of -$5.27 million. Return on equity is -10.66, and return on assets is -1.76, indicating severe capital inefficiency in the current period. Operating cash flow burned -$3.54 million, with free cash flow matching this outflow as capital expenditures were zero. These figures highlight a business model entirely dependent on external capital infusion to sustain research and development activities, with no internal cash generation from commercial sales.

The company’s revenue mix is effectively non-existent from commercial sources, with operations funded through a combination of equity offerings, warrant exercises, and government grants. Filing observations reference a BARDA contract, indicating exposure to U.S. government biodefense funding streams. There is no disclosed geographic revenue concentration from commercial sales; however, the company’s operational footprint and regulatory interactions are primarily domestic, with strategic implications tied to the U.S. Strategic National Stockpile. The lack of diversified revenue streams concentrates risk on the success of specific vaccine candidates and the continuity of government or private capital support.

Growth trajectory is defined by capital consumption rather than revenue expansion. The historical data shows consistent net losses and negative operating cash flows, with no positive revenue trend to offset burn. The company executed a reverse stock split in January 2026, a corporate action typically taken to maintain exchange listing requirements or improve share price perception, which often precedes further dilutive financing. The absence of revenue growth and the continuous cash burn rate suggest that near-term "growth" will be measured in capital raised rather than top-line expansion, with significant uncertainty regarding the timeline to commercialization.

Risk factors are elevated, with the company explicitly citing substantial doubt about its ability to continue as a going concern in its Q1 2026 filings. Liquidity risk is rated high, and dilution risk is medium, driven by the extensive warrant overhang and recent at-the-market offerings. Key flags include the proximity of the current ratio to minimum comfort levels and the explicit mention of dilution or offering risks in source documents. The company’s dependence on securing additional capital to continue planned operations introduces a binary risk profile: failure to raise funds could lead to insolvency, while successful raises will likely result in significant shareholder dilution.

Recent events include the filing of a Q1 2026 10-Q which details warrant exercise inducement letters and subsequent events related to capital raises. The company has engaged in multiple equity offerings throughout 2025 and early 2026, including February, July, September, and December 2025 offerings, each accompanied by warrants. Analyst estimates show a mean price target of $186.67, which is vastly disconnected from the current market price of $0.90, suggesting either extreme speculative interest or data anomalies in analyst coverage. The mean recommendation is 2.00 (Buy), with two buy ratings and no holds or sells, indicating limited but positive analyst sentiment despite the fundamental risks.

Geovax Labs, Inc. (GOVX) has recorded two notable additions to its shareholder base, marking the first analysis for the ticker with no prior basis for delta computation. These changes involve new institutional holdings detected on June 28, 2026, signaling initial accumulation activity for the company. The first addition involves an investor (ID 465) holding 244,163 shares as of December 31, 2025. This position represents a portfolio weight of approximately 6.05e-07% and a value of $0.042 million. The second addition involves a different investor (ID 466) holding 27,565 shares as of June 30, 2024, with a portfolio weight of approximately 1.99e-06% and a value of $0.088 million. These holdings contribute to Geovax Labs' current profile, which includes seven top holders. The company currently has no listed officers, no analyst coverage, and no index memberships, according to available data. The emergence of these specific institutional positions provides a baseline for future monitoring of ownership concentration and investor interest in Geovax Labs. As the first recorded analysis, these data points establish the initial reference for tracking changes in the company's shareholder structure.

Operating income -$5.3M.

• ▍Operating income -$5.3M

Operating income -$17.2M.

• ▍Operating income -$17.2M

Operating income -$10.8M.

• ▍Operating income -$10.8M

Operating income -$21.6M.

• ▍Operating income -$21.6M

Operating income -$25.1M.

• ▍Operating income -$25.1M

Operating income -$25.1M.

• ▍Operating income -$25.1M

Operating income -$26.7M.

• ▍Operating income -$26.7M

Operating income -$26.7M.

• ▍Operating income -$26.7M